NuGen Medical Devices Inc. announced it has engaged Basic Pharma Technologies, a pharmaceutical company located in the Netherlands, to perform an assessment and feasibility study, which will include validation testing of semaglutide if administered using NuGen's needle free injection device, InsuJetTM. Semaglutide is the drug known as Ozempic and it is currently administered by a pen-needle method. integrity testing of semaglutides being administered via InsuJetTM will be conducted over a seven-to-eight-month period comprising of three phases: Phase 1 will comprise of regulatory compliance and literature search, method development literature search, and reference standard research and sourcing.

Phase 2 will comprise of feasibility study method and development. Phase 3 will comprise of QC method and writing and writing and writing and validating, method and validation protocol writing review and effectiveness, method validation study execution and data review, method validation report writing and effectiveness and sample measurement and reporting of sample measurement. Overall of Phase 3, estimated at four-to-five-months, will determine a Go/No-Go outcome which will be reported to shareholders.

Efficacy of InsuJetTM: Efficacy of Insu JetTM shows improved insulin uptake of upwards of 40%. Clinical studies, certificates, or InsuJetTM reports are found at: . Semaglutide is a GLP-1 receptor agonist, meaning that it mimics the action of human incretin glucagon-like peptide-1 (GLP-1).

This improves insulin secretion and glycemic control, and reduces appetite and calorie intake. It was developed by Novo Nordisk in 2012 as a longer-acting alternative to liraglutide, an insulin for type 2 diabetics but also for administration to obese patients and marketed under the trade name "Ozempic". Ozempic has recently come into the public eye, with numerous celebrities and influencers claiming to have lost weight with the drug.

The result was product shortages, so that the levy was regulated in many places.